148 related articles for article (PubMed ID: 32088382)
1. Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Zheng C; Xu Y; Chen G; Tan Y; Zeng W; Wang J; Cheng C; Yang X; Nie S; Zhang Z; Cao X
Neurobiol Dis; 2020 Jun; 139():104807. PubMed ID: 32088382
[TBL] [Abstract][Full Text] [Related]
2. Activation of mGlu
Tan Y; Cheng C; Zheng C; Zeng W; Yang X; Xu Y; Zhang Z; Ma Z; Xu Y; Cao X
Pharmacol Biochem Behav; 2023 Oct; 231():173637. PubMed ID: 37714223
[TBL] [Abstract][Full Text] [Related]
3. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
Huang YT; Chen YW; Lin TY; Chen JC
Neurobiol Dis; 2024 Apr; 193():106452. PubMed ID: 38401650
[TBL] [Abstract][Full Text] [Related]
4. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
[TBL] [Abstract][Full Text] [Related]
5. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia.
Finlay CJ; Jackson MJ; Fisher R; Bundgaard C; Rose S; Duty S
J Parkinsons Dis; 2024; 14(2):245-259. PubMed ID: 38427500
[TBL] [Abstract][Full Text] [Related]
7. Additive effects of mGluR
Nuara SG; Gourdon JC; Maddaford S; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2021 Dec; 394(12):2381-2388. PubMed ID: 34550406
[TBL] [Abstract][Full Text] [Related]
8. Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Murakami Y; Nishijima H; Nakamura T; Furukawa T; Kinoshita I; Kon T; Suzuki C; Tomiyama M
Neurosci Lett; 2023 May; 806():137248. PubMed ID: 37061023
[TBL] [Abstract][Full Text] [Related]
9. 4'-fluorocannabidiol associated with capsazepine restrains L-DOPA-induced dyskinesia in hemiparkinsonian mice: Contribution of anti-inflammatory and anti-glutamatergic mechanisms.
Dos Santos Pereira M; Dias de Abreu GH; Vanderlei LCA; Raisman-Vozari R; Guimarães FS; Lu HC; Michel PP; Del Bel E
Neuropharmacology; 2024 Jun; 251():109926. PubMed ID: 38554815
[TBL] [Abstract][Full Text] [Related]
10. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
[TBL] [Abstract][Full Text] [Related]
11. Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.
Bi Y; Wang P; Yu J; Wang Z; Yang H; Deng Y; Guan J; Zhang W
CNS Neurosci Ther; 2023 Oct; 29(10):2998-3013. PubMed ID: 37122156
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
13. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats.
Huang Y; Shu H; Li L; Zhen T; Zhao J; Zhou X; Luo W
ASN Neuro; 2018; 10():1759091418811021. PubMed ID: 30439288
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
[TBL] [Abstract][Full Text] [Related]
16. Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Dupre KB; Cruz AV; McCoy AJ; Delaville C; Gerber CM; Eyring KW; Walters JR
Neurobiol Dis; 2016 Feb; 86():1-15. PubMed ID: 26586558
[TBL] [Abstract][Full Text] [Related]
17. Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Ueno T; Yamada J; Nishijima H; Arai A; Migita K; Baba M; Ueno S; Tomiyama M
Neurobiol Dis; 2014 Apr; 64():142-9. PubMed ID: 24398173
[TBL] [Abstract][Full Text] [Related]
18. Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Paquette MA; Martinez AA; Macheda T; Meshul CK; Johnson SW; Berger SP; Giuffrida A
Eur J Neurosci; 2012 Nov; 36(9):3224-34. PubMed ID: 22861201
[TBL] [Abstract][Full Text] [Related]
19. The selective 5-HT
Depoortere R; Johnston TH; Fox SH; Brotchie JM; Newman-Tancredi A
Parkinsonism Relat Disord; 2020 Sep; 78():151-157. PubMed ID: 32846366
[TBL] [Abstract][Full Text] [Related]
20. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
